OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-09-30-accounts

Page
Report ofthe Trustees I to 4
Report ofthe Independent
Auditors
5 to 8
Statement ofFinancial Activities
Balance Sheet 10
Notes to the Financial Statements 11 to 17
Detailed Statement ofFinancial Activities 18 to 19

30.9.21 30.9.20
Unrestricted Restricted Total Total
fund fund funds funds
Notes
INCOME AND ENDOWMENTS FROM
Donations
and legacies
19,557 27,946 47,503 18,884
Charitable
activities
Research into and education on oncology 28,528 28,528 37,584
Investment
income
2 9,179 36,771 45,950 40,188
Other income 1300 1380 140D
Total 28,736 94,625 123,361 98,056
EXPENDITURE ON
Raising funds 3 3,600 14,452 18,052 13,339
Charitable
activities
Research into and education on oncology 12,411 54,497 66,908 82,412
Total 16,011 68,949 84,960 95,751
Net gains/(losses)
on
investments ~25969 1D4,251 130226 ~120062
NET INCOME/(EXPENDITURE) 38,694 129,933 168,627 (116,557)
RECONCILIATION OF FUNDS
Total funds brought forward 279,437 1,121,867 1,401,304 1,517,861
TOTAL FUNDS CARRIED FORWARD 310,131 1251 800 1569,931 I 401 3D4
30.9.21 30.9.20
Unrestricted Restricted Total Total
Notes fund
f
fund funds funds
FIXEDASSETS
Investments 11 175,566 1,093,704 1,269,270 1,112,186
CURRENT ASSETS
Debtors
Cash at bank
12 2,593
~150352
17,534
161,698
20,127
~312050
15,985
284,280
152,945 179,232 332,177 300,265
CREDITORS
Amounts
falling due within one year
13 (10,380) (21,136) (31,516) (11,147)
NET CURRENT ASSETS 142,565 158,096 300,661 289,118
TOTAL ASSETSLESSCURRENT
LIABILITIES 318,131 1,251,800 1,569,931 1,401,304
NET ASSETS ~325 131 1 251,SDD 1569 932 1,401,304
FUNDS 14
Unrestricted
funds
Restricted
funds
318,131
1,251,800
279,437
1,121,867
TOTAL FUNDS 1,569,931 1,401,304

Short term trade creditors are measured at the transaction at the transaction price. Other financial liabilities,
including
liabilities,
including
bank loans,
are measured
initially
at
fair value, net of transaction costs, and are measured subsequently at amortised
cost
using the effective interest method.
INVESTMENT INCOME
30.9.21
f
30.9.20
f
Other investment
income
45,914 39,774
Deposit account interest 36 414
45,950 40,188
RAISING FUNDS
Investment
management
costs
30.9.21
f
30.9.20
f
Portfolio management 18,052 13,339

Governance
Other costs Totals
f f
Research into and education on oncology ~9246 ~4800 14,046
NET INCOME/(EXPENDITURE)
Net income/(expenditure) is stated atter charging/(crediting):
30.9.21 30.9.20
Auditors' remuneration 3,600 3,600
Auditors' remuneration for non-audit work ~1200 1,200

30.9.21 30.9.20
f
Wages and salaries 45,667 54,459
45,667 54,459
Staffcosts are solely made up ofwages recharged made up ofwages recharged t'rom various trusts during the year.
The average monthly number ofemployees during the year was as follows:
Research staff 30.9.21
2
30.9.20
=2

During the year an ex-grati
for the work undertaken
in
a payment ofI3,000 was made to the volunteer
bookke
managing
the charities accounting
function.
a payment ofI3,000 was made to the volunteer
bookke
managing
the charities accounting
function.
eper for the c harity as thanks
COMPARATIVES FOR THE STATEMENT OFFINANCIAL ACTIVITIES
Unrestricted Restricted Total
fund fund funds
8
INCOME AND ENDOWMENTS FROM
Donations
and legacies
7,529 11,355 18,884
Charitable
activities
Research into and education on oncology 37,584 37,584
investment
income
8,064 32,124 40,188
Other income 1,400 1,400
Total 15,593 82,463 98,056
EXPENDITURE ON
Raising funds 2,658 10,681 13,339
Charitable
activities
Research into and education on oncology 12,273 70,139 82,412
Total 14,931 80,820 95,751
Net gains/(losses)
on investments
~23,686 ~96.)36) ~))8,862)
NET INCOME/(EXPENDITURE) (23,024) (93,533) (116,557)
RECONCILIATION
OFFUNDS
Total funds brought forward 302,461 1,215,400 1,517,861
TOTAL FUNDS CARRIED FORWARD 279,437 1,121,867 1 401,304

Listed
investments
MARKET VALUE
At 1 October 2020 1,112,186
Additions 508,074
Disposals (450384)
Revaluations 99,394
At 30September 2021 1,269,270
NET BOOK VALUE
At 30September 2021 1,269,270
At 30 September 2020 1,112,186
There were no investment assets outside the UK.

Listed
investments
Valuation in 2021 99,394
Cost 1169976
1269276
DEBTORS: AMOUNTS FALLING DUK WITHIN ONE YEAR
30.9.21 30.9.20
g I
Other debtors 13,192 3,153
Prepayments and accrued income ~6935 12,832
20,127 15,985
13. CREDITORS: CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR AMOUNTS FALLING DUE WITHIN ONE YEAR AMOUNTS FALLING DUE WITHIN ONE YEAR AMOUNTS FALLING DUE WITHIN ONE YEAR AMOUNTS FALLING DUE WITHIN ONE YEAR AMOUNTS FALLING DUE WITHIN ONE YEAR AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.21 30.9.20
f
Trade creditors 23,716 410
Accrued expenses ~7000 ~10 737
31,516 11,147
14. MOVEMENT IN FUNDS
The restricted funds below, are funds held by the Trust on behalf ofConsultants and applied for their research
projects. When funds are received for a specific consultant, they are allocated the relevant Consultants
fund
under Restricted Funds. Any other funds,
non-specific,
are allocated
to the General fund, under Unrestricted
Funds.
The Development fund is a grant based fund to cover general administration expenses and staff development.
Cyberknife
and
Head and Neck Funds
are restricted
for specific treatments and can be used by named
fund
holders.
At incondng Resources Gains Trsnslers
01.10.20
f
Resources expended
f
nnd
losses
5
betweea
fundsf
At
30.09.21
5
Unrestricted
funds
General
Breast
118,794
46,516
16,454
1,524
(13471)
(1,249)
11,040
4,323
133,017
51,114
Development
Fightiug Breast
85,979 2,817 (1,108) 7,990 95,678
Cancer 28,148 7 41 383 2,616 38,322
279,437 28,736 (16,011) 25,969 318,131
Restricted funds
FrofP Hoskin
Dr AMskris
Dr P Ostler
Dr C Lemon/ Dr K
527417
91,454
25,287
55,650
2,997
829
(44,728)
(2,259)
(326)
48,995
8,499
2,350
587,134
100,69i
28,140
Chiu
Dr M Harrison
Dr N Shah
Dr D Miles
Dr SMewdsley
Dr RAlonzi
Development
Cyberkoife
Fund
Dr Westbuiy
176/68
18,540
65,279
96,678
13,665
20,550
68,170
8,944
22,875
607
2,139
3,418
448
1,051
2/34
515
(15Z58)
(239)
(841)
(3,473)
(176)
(298)
(878)
(351)
16,409
1,723
6,067
8/84
t/70
tg10
6,335
831
200,594
20,631
72,644
105,607
15,207
23,213
75,861
9s)39
/Guppy
Dr Neel Bhuvs
Brschy
6,071
3,444
199
2463
300
(78)
(44)
564
320
6,756
5,083
300
~1121,867 94,625 ~68,949) ~104257 tZ51,800

TOTAL FUNDS
~1401304 123361 ~04 960) ~130226 - ~1569Tt31

Detailed Statement ofFinancial Activities Detailed Statement ofFinancial Activities
for the Year Ended 30Se tember 2021
30.9.21 30.9.20
INCOME AND ENDOWMENTS
Donations
and legacies
Donations 30,180 17,884
Legacies ~17 323 1 000
47,503 18,884
Investment
income
Other investment
income
45,914 39,774
Deposit account interest 36 414
45,950 40,188
Charitable
activities
Grants 28,528 37,584
Other income
Training
income
1,080 1,400
Other income 300
1
80
1,400
Total incoming resources 123,361 98,056
EXPENDITURE
Investment
management
costs
Portfolio management 18,052 13,339
Charitable
activities
Research salaries 45,667 54,459
Research materials 4,919 1,705
Transport
expenses
90
Lecture fees (110)
Conference 1,996 6,527
Computer
expenses
280 4,412
52,862 67,083
Support costs
Other
Subscriptions 1,432 1,526
Administrative
expenses
7,576 8,288
Travelling 238 715
9,246 10,529
for the Year Ended 30 S e tember 202 1
30.9.21 30.9.20
Other
Governance
costs
Auditors'
remuneration
Auditors'
remuneration
for non-audit work 3,600
~1200
3,600
1200
~4800 4,800
Total resources expended ~84 960 95,751
Net income before gains and losses 38,401 2,305
Realised recognised
gains and losses
Realised gains/(losses)
on fixed asset
investments 24,858 f28,659)
Net income/(expenditure) 63,259 ~26,354)